These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37537423)

  • 1. Solid Form Screenings in Pharmaceutical Development: a Perspective on Current Practices.
    Gui Y
    Pharm Res; 2023 Oct; 40(10):2347-2354. PubMed ID: 37537423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.
    Ticehurst MD; Marziano I
    J Pharm Pharmacol; 2015 Jun; 67(6):782-802. PubMed ID: 25677227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
    Elder DP; Patterson JE; Holm R
    J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid form screening--a review.
    Aaltonen J; Allesø M; Mirza S; Koradia V; Gordon KC; Rantanen J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of pharmaceutically relevant materials at the solid state employing chemometrics methods.
    Calvo NL; Maggio RM; Kaufman TS
    J Pharm Biomed Anal; 2018 Jan; 147():538-564. PubMed ID: 28666554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of computed crystal energy landscapes to aid solid-form development.
    Price SL; Reutzel-Edens SM
    Drug Discov Today; 2016 Jun; 21(6):912-23. PubMed ID: 26851154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental cocrystal screening and solution based scale-up cocrystallization methods.
    Malamatari M; Ross SA; Douroumis D; Velaga SP
    Adv Drug Deliv Rev; 2017 Aug; 117():162-177. PubMed ID: 28811184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in the quantitative analytical methods of drug polymorphism].
    Ma LW; Du W; Zhao CS
    Yao Xue Xue Bao; 2011 Aug; 46(8):896-903. PubMed ID: 22007512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism and crystallization of active pharmaceutical ingredients (APIs).
    Lu J; Rohani S
    Curr Med Chem; 2009; 16(7):884-905. PubMed ID: 19275600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids.
    Shah B; Kakumanu VK; Bansal AK
    J Pharm Sci; 2006 Aug; 95(8):1641-65. PubMed ID: 16802362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
    Meng F; Gala U; Chauhan H
    Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Islatravir Case Study for Enhanced Screening of Thermodynamically Stable Crystalline Anhydrate Phases in Pharmaceutical Process Development by Hot Melt Extrusion.
    Skomski D; Varsolona RJ; Su Y; Zhang J; Teller R; Forster SP; Barrett SE; Xu W
    Mol Pharm; 2020 Aug; 17(8):2874-2881. PubMed ID: 32511923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of industrially recognized polymers and manufacturing processes for amorphous solid dispersion based formulations.
    Saha SK; Joshi A; Singh R; Dubey K
    Pharm Dev Technol; 2023 Sep; 28(7):678-696. PubMed ID: 37427544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An industrial perspective on co-crystals: Screening, identification and development of the less utilised solid form in drug discovery and development.
    Kendall T; Stratford S; Patterson AR; Lunt RA; Cruickshank D; Bonnaud T; Scott CD
    Prog Med Chem; 2021; 60():345-442. PubMed ID: 34147205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-state analysis of the active pharmaceutical ingredient in drug products.
    Newman AW; Byrn SR
    Drug Discov Today; 2003 Oct; 8(19):898-905. PubMed ID: 14554018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polymorph transformation of solid drugs].
    Zhang Q; Mei XF
    Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the scope of crystal form evaluation in pharmaceutical science.
    Peterson ML; Hickey MB; Zaworotko MJ; Almarsson O
    J Pharm Pharm Sci; 2006; 9(3):317-26. PubMed ID: 17207415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple approaches to pharmaceutical polymorphism investigation--a case study.
    Li H; Kiang YH; Jona J
    Eur J Pharm Sci; 2009 Dec; 38(5):426-32. PubMed ID: 19748574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.